MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
982.82
+16.73
+1.73%
After Hours: 982.00 -0.82 -0.08% 19:57 03/01 EST
OPEN
967.50
PREV CLOSE
966.09
HIGH
988.13
LOW
966.09
VOLUME
370.54K
TURNOVER
0
52 WEEK HIGH
998.33
52 WEEK LOW
684.81
MARKET CAP
107.88B
P/E (TTM)
28.26
1D
5D
1M
3M
1Y
5Y
This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag
Some exchange-traded funds that buy biotech stocks are rallying in 2024. The Russell 2000 index of U.S. Small-cap stocks is up 1.4% this year. The SPDR S&P Biotech ETF has soared 12.6% in February. Small-cap tech equities are lagging large-cap equities.
MarketWatch · 3d ago
Intellia Therapeutics Is On The Move
Shares of genome editing therapy concern Intellia Therapeutics, Inc. Have move up by a third in the past month. The company has potential cures for HAE and ATTR-CM within its pipeline, but commercialization is years away. The stock is still down 10% since Bret Jensen last looked at the company in April 2023. With its stock likely to drift, the options market provides a way to generate significant returns with meaningful downside protection. Intellian is developing a CRISPR-Cas9 genome editing platform.
Seeking Alpha · 3d ago
Stocks Gain on Relief That Price Pressures are Abating
NASDAQ · 3d ago
Stocks Close Higher as Inflation Concerns Ease
U.S. Stock indexes on Thursday posted moderate gains on signs inflation pressures are easing. The Fed's preferred inflation gauge rose 2.8% in January, the slowest pace in 2-3/4 years. The Jan MNI Chicago PMI, Jan pending home sales, and Jan jobless claims are all positive for the economy. Chip stocks also rallied after Citigroup says it is "wildly bullish" on the sector.
Barchart · 3d ago
Nasdaq 100 Movers: XEL, MNST
NASDAQ · 3d ago
Stocks Climb as Bond Yields Fall on Dovish U.S. Economic Reports
Chip stocks are rallying after Citigroup says it is 'wildly bullish' on the sector. The S&P 500 and Nasdaq are moderately higher this morning on signs inflation pressures are easing. The Jan core PCE deflator rose 2.8% in January, the slowest pace in 2-3/4 years. Jobless claims, the Jan MNI Chicago PMI, and Jan pending homes sales are also positive for stocks.
Barchart · 3d ago
Regeneron Pharmaceuticals Reaches Analyst Target Price
NASDAQ · 4d ago
Biotech Stocks Facing FDA Decision In March 2024
NASDAQ · 4d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.